Legend Biotech Begins CEO Succession

Company Legend Biotech Event Type Leadership Transition (CEO and Board Resignation) Modality Autologous BCMA-directed CAR-T cell therapy (commercial franchise context) Platform CARVYKTI (ciltacabtagene autoleucel), developed and marketed with Johnson & Johnson Indication Relapsed or refractory multiple myeloma Summary Legend Biotech disclosed that Ying Huang resigned…